Companies › Rovi Pharmaceuticals Laboratories
1 active drug program in 43 registered trials: 26 Phase 2, 11 Phase 3, 4 Phase 4, 2 Phase 1; Genitourinary, Metabolic and endocrine, Oncology, Other; next expected readout May 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Letrozole Cytochrome P450 19A1 inhibitor | CYP19A1 | Phase 1 | Hormone Receptor Positive Early Breast Cancer; Polycystic Ovary Syndrome; Abortion in First Trimester; Miscarriage in First Trimester … | May 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT00999804 | Letrozole | Phase 2 | Breast Cancer | Oncology | Nov 2014 |
| NCT05206448 | Letrozole | Phase 4 | Polycystic Ovary Syndrome | Metabolic and endocrine | Apr 2024 |
| NCT04272801 | Letrozole | Phase 2 | Breast Cancer Female | Oncology | Jun 2024 |
| NCT06244745 | Letrozole | Phase 3 | Luteinised Follicular Cyst | Genitourinary | May 2025 |
| NCT05341817 | Letrozole | Phase 4 | Abortion in First Trimester | Other | Aug 2025 |
| NCT07160855 | Letrozole | Phase 4 | Miscarriage in First Trimester | Other | Nov 2025 |
| NCT05190094 | Letrozole | Phase 2 | Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer | Oncology | Dec 2025 |
| NCT07616973 | Letrozole | Phase 3 | Infertility Drugs | Metabolic and endocrine | May 2026 |
| NCT04486911 | Letrozole | Phase 2 | Breast Cancer | Oncology | Dec 2026 |
| NCT04393285 | Letrozole | Phase 2 | Endometrial Cancer | Oncology | Dec 2026 |
| NCT07842796 | Letrozole | Phase 2 | Ectopic Pregnancy | Other | Dec 2026 |
| NCT06354439 | Letrozole | Phase 4 | Ectopic Pregnancy | Other | Dec 2026 |
| NCT03673124 | Letrozole | Phase 2 | Low Grade Serous Carcinoma | Oncology | Dec 2026 |
| NCT01272037 | Letrozole | Phase 3 | Breast Ductal Carcinoma In Situ | Oncology | Jan 2027 |
| NCT04095364 | Letrozole | Phase 3 | Low Grade Fallopian Tube Serous Adenocarcinoma | Oncology | Feb 2027 |
| NCT05247268 | Letrozole | Phase 2 | Endometrial Neoplasm Malignant Stage I | Oncology | Mar 2027 |
| NCT06394804 | Letrozole | Phase 2 | Low-Grade Serous Ovarian Cancer | Oncology | Apr 2027 |
| NCT05472792 | Letrozole | Phase 2 | Breast Cancer | Oncology | Apr 2027 |
| NCT05900206 | Letrozole | Phase 2 | Breast Cancer | Oncology | Apr 2027 |
| NCT04111978 | Letrozole | Phase 3 | Ovarian Neoplasm Epithelial | Oncology | Jul 2027 |
| NCT06390904 | Letrozole | Phase 2 | Atypical Endometrial Hyperplasia | Metabolic and endocrine | Jul 2027 |
| NCT06366347 | Letrozole | Phase 2 | Endometrial Cancer | Oncology | Sep 2027 |
| NCT07014410 | Letrozole | Phase 2 | Breast Cancer | Oncology | Dec 2027 |
| NCT05872204 | Letrozole | Phase 2 | Low Grade Serous Ovarian Carcinoma | Oncology | Jan 2028 |
| NCT05316935 | Letrozole | Phase 2 | Endometrial Neoplasms | Oncology | Mar 2028 |
| NCT06379113 | Letrozole | Phase 2 | Endometrial Neoplasms | Oncology | Mar 2028 |
| NCT04568616 | Letrozole | Phase 2 | Breast Cancer | Oncology | Apr 2028 |
| NCT01068249 | Letrozole | Phase 2 | Endometrial Cancer | Oncology | Apr 2028 |
| NCT07401381 | Letrozole | Phase 1 | Hormone Receptor Positive Early Breast Cancer | Oncology | May 2028 |
| NCT05649956 | Letrozole | Phase 2 | Uterine Leiomyosarcoma | Oncology | Jul 2028 |
| NCT06044623 | Letrozole | Phase 3 | Metastatic Breast Cancer | Oncology | Oct 2028 |
| NCT03900637 | Letrozole | Phase 2 | Breast Cancer | Oncology | Dec 2028 |
| NCT02221999 | Letrozole | Phase 2 | Tubular Breast Cancer | Oncology | Jan 2029 |
| NCT06276868 | Letrozole | Phase 2 | Breast Cancer | Oncology | Jun 2029 |
| NCT06507618 | Letrozole | Phase 3 | Breast Cancer Female | Oncology | Jun 2029 |
| NCT05601700 | Letrozole | Phase 3 | Carcinoma, Ovarian Epithelial | Oncology | Sep 2029 |
| NCT07483307 | Letrozole | Phase 2 | Breast Cancer | Oncology | Mar 2030 |
| NCT04134598 | Letrozole | Phase 3 | Breast Cancer | Oncology | Mar 2030 |
| NCT00310180 | Letrozole | Phase 3 | Breast Adenocarcinoma | Oncology | Sep 2030 |
| NCT05297617 | Letrozole | Phase 2 | Breast Cancer | Oncology | Nov 2030 |
| NCT04852887 | Letrozole | Phase 3 | Stage I Breast Cancer | Oncology | Apr 2031 |
| NCT06139107 | Letrozole | Phase 1 | Breast Cancer | Oncology | Sep 2032 |
| NCT04293393 | Letrozole | Phase 2 | Early Breast Cancer | Oncology | Feb 2033 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.